Insmed (INSM +20%) soars today on the back of an enthusiastic investor response to its lead drug Arikace. Lazard joins the lovefest, initiating the shares with a Buy and an aggressive $ 21 price target. The firm says it expects positive results for Phase 3 and Phase 2b studies for for the drug, with the potential for treating a host of maladies. Additionally, its once-daily dose regimen is convenient for patients, which will make it even more competitive. Lazard thinks revenue from Arikace could top $600M by 2020.
Does anyone have a link to the complete Lazard upgrade. Thanks.
Seeking Alpha, Crammer and the Fools make me nervous, they have burn me few times.
I only trust info coming directly from the Company Officers.
ABOUT SCOTT MATUSOW AUTHOR OF THIS MORNING FLAG, Matusow is strong poker playing online.
I have about fifteen years of stock market experience which include trading, investing, and managing my family’s trust as well as my personal account.
I have had the most success in trading/investing in smaller cap growth companies. I am not 'officially trained' in the markets, which allows me to see things 'outside the box.' I use my ability to read situations and emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements. Using these allowed for me to completely divest my own and my family's money near the top of the market before the 2008 financial crisis. I will also be opening a training site soon for traders who want to learn to think outside the box for maximum profits